154 related articles for article (PubMed ID: 19502558)
21. Cardiac myotrophin exhibits rel/NF-kappa B interacting activity in vitro.
Sivasubramanian N; Adhikary G; Sil PC; Sen S
J Biol Chem; 1996 Feb; 271(5):2812-6. PubMed ID: 8576259
[TBL] [Abstract][Full Text] [Related]
22. The rise and fall of myotrophin in heart failure.
McMurray JJ; Hillier C
J Am Coll Cardiol; 2003 Aug; 42(4):726-7. PubMed ID: 12932610
[No Abstract] [Full Text] [Related]
23. Morphological and functional changes in cardiac myocytes isolated from mice overexpressing TNF-alpha.
Janczewski AM; Kadokami T; Lemster B; Frye CS; McTiernan CF; Feldman AM
Am J Physiol Heart Circ Physiol; 2003 Mar; 284(3):H960-9. PubMed ID: 12578819
[TBL] [Abstract][Full Text] [Related]
24. The Human Myotrophin Variant Attenuates MicroRNA-Let-7 Binding Ability but Not Risk of Left Ventricular Hypertrophy in Human Essential Hypertension.
Wang Y; Chen J; Song W; Wang Y; Chen Y; Nie Y; Ye Z; Hui R
PLoS One; 2015; 10(8):e0135526. PubMed ID: 26274321
[TBL] [Abstract][Full Text] [Related]
25. NF-kappaB activation is required for the development of cardiac hypertrophy in vivo.
Li Y; Ha T; Gao X; Kelley J; Williams DL; Browder IW; Kao RL; Li C
Am J Physiol Heart Circ Physiol; 2004 Oct; 287(4):H1712-20. PubMed ID: 15142841
[TBL] [Abstract][Full Text] [Related]
26. Myotrophin/V-1 does not act as an extracellular signal to induce myocyte hypertrophy.
Knuefermann P; Shi SP; Chen P; Sakata Y; Baumgarten G; Sivasubramanian N
Tex Heart Inst J; 2006; 33(3):281-9. PubMed ID: 17041682
[TBL] [Abstract][Full Text] [Related]
27. Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy.
Suckau L; Fechner H; Chemaly E; Krohn S; Hadri L; Kockskämper J; Westermann D; Bisping E; Ly H; Wang X; Kawase Y; Chen J; Liang L; Sipo I; Vetter R; Weger S; Kurreck J; Erdmann V; Tschope C; Pieske B; Lebeche D; Schultheiss HP; Hajjar RJ; Poller WC
Circulation; 2009 Mar; 119(9):1241-52. PubMed ID: 19237664
[TBL] [Abstract][Full Text] [Related]
28. S100A8/MYD88/NF-қB: a novel pathway involved in cardiomyocyte hypertrophy driven by thyroid hormone.
Takano APC; Munhoz CD; Moriscot AS; Gupta S; Barreto-Chaves MLM
J Mol Med (Berl); 2017 Jun; 95(6):671-682. PubMed ID: 28161820
[TBL] [Abstract][Full Text] [Related]
29. Nuclear Localization Leucine-Rich-Repeat Protein 1 Deficiency Protects Against Cardiac Hypertrophy by Pressure Overload.
Zong J; Li FF; Liang K; Dai R; Zhang H; Yan L; Liu JL; Xu LH; Qian WH
Cell Physiol Biochem; 2018; 48(1):75-86. PubMed ID: 30001530
[TBL] [Abstract][Full Text] [Related]
30. Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy.
Kunisada K; Negoro S; Tone E; Funamoto M; Osugi T; Yamada S; Okabe M; Kishimoto T; Yamauchi-Takihara K
Proc Natl Acad Sci U S A; 2000 Jan; 97(1):315-9. PubMed ID: 10618415
[TBL] [Abstract][Full Text] [Related]
31. Requirement of nuclear factor-kappaB in angiotensin II- and isoproterenol-induced cardiac hypertrophy in vivo.
Freund C; Schmidt-Ullrich R; Baurand A; Dunger S; Schneider W; Loser P; El-Jamali A; Dietz R; Scheidereit C; Bergmann MW
Circulation; 2005 May; 111(18):2319-25. PubMed ID: 15870116
[TBL] [Abstract][Full Text] [Related]
32. Alterations in cardiac gene expression during the transition from stable hypertrophy to heart failure. Marked upregulation of genes encoding extracellular matrix components.
Boluyt MO; O'Neill L; Meredith AL; Bing OH; Brooks WW; Conrad CH; Crow MT; Lakatta EG
Circ Res; 1994 Jul; 75(1):23-32. PubMed ID: 8013079
[TBL] [Abstract][Full Text] [Related]
33. Divergent tumor necrosis factor receptor-related remodeling responses in heart failure: role of nuclear factor-kappaB and inflammatory activation.
Hamid T; Gu Y; Ortines RV; Bhattacharya C; Wang G; Xuan YT; Prabhu SD
Circulation; 2009 Mar; 119(10):1386-97. PubMed ID: 19255345
[TBL] [Abstract][Full Text] [Related]
34. Myotrophin/V-1, a protein up-regulated in the failing human heart and in postnatal cerebellum, converts NFkappa B p50-p65 heterodimers to p50-p50 and p65-p65 homodimers.
Knuefermann P; Chen P; Misra A; Shi SP; Abdellatif M; Sivasubramanian N
J Biol Chem; 2002 Jun; 277(26):23888-97. PubMed ID: 11971907
[TBL] [Abstract][Full Text] [Related]
35. Effects of interfering RNA of α-1,3-galactosyltransferase and nuclear factor-kappa B on cardiac xenotransplantation.
Cao JS; Qi F; Lu CY; Gu YC; Zhu LW
Transpl Immunol; 2014 Sep; 31(3):173-82. PubMed ID: 25128705
[TBL] [Abstract][Full Text] [Related]
36. Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes.
Horio T; Nishikimi T; Yoshihara F; Matsuo H; Takishita S; Kangawa K
Hypertension; 2000 Jan; 35(1 Pt 1):19-24. PubMed ID: 10642269
[TBL] [Abstract][Full Text] [Related]
37. Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice.
Duan SZ; Ivashchenko CY; Russell MW; Milstone DS; Mortensen RM
Circ Res; 2005 Aug; 97(4):372-9. PubMed ID: 16051889
[TBL] [Abstract][Full Text] [Related]
38. TGF-beta1 induces cardiac hypertrophic responses via PKC-dependent ATF-2 activation.
Lim JY; Park SJ; Hwang HY; Park EJ; Nam JH; Kim J; Park SI
J Mol Cell Cardiol; 2005 Oct; 39(4):627-36. PubMed ID: 16125722
[TBL] [Abstract][Full Text] [Related]
39. Myocyte-specific enhancer factor 2C: a novel target gene of miR-214-3p in suppressing angiotensin II-induced cardiomyocyte hypertrophy.
Tang CM; Liu FZ; Zhu JN; Fu YH; Lin QX; Deng CY; Hu ZQ; Yang H; Zheng XL; Cheng JD; Wu SL; Shan ZX
Sci Rep; 2016 Oct; 6():36146. PubMed ID: 27796324
[TBL] [Abstract][Full Text] [Related]
40. Captopril modifies gene expression in hypertrophied and failing hearts of aged spontaneously hypertensive rats.
Brooks WW; Bing OH; Conrad CH; O'Neill L; Crow MT; Lakatta EG; Dostal DE; Baker KM; Boluyt MO
Hypertension; 1997 Dec; 30(6):1362-8. PubMed ID: 9403554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
